ClinicalTrials.gg
Not yet recruitingNCT07558941Updated Apr 30, 2026

Conservative Versus Surgical Treatment of Gartland Type II Supracondylar Humeral Fractures in Children - Which One ?

An interventional study of Conservative treatment by casting and surgical treatment via percutaneous pinning UGA in Humeral Fractures, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 12 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
1 Year to 12 Years
Sex
All
01

Study summary

The primary aim of this research is to compare the efficacy of conservative treatment versus surgical treatment for Gartland type II supracondylar humerus fractures in children. The comparison focuses on assessing differences in clinical outcomes functional recovery times, and complication rates between the two treatment groups.

Read the detailed description

Supracondylar Humerus Fractures are the most common type of elbow fracture in children, typically occurring between the ages of five and seven. These injuries are critical due to their proximity to major neurovascular structures, making prompt and appropriate management essential to prevent severe complications. The vast majority (approximately 98%) of SCHFs are extension-type injuries, resulting from a fall onto an outstretched hand with the elbow hyperextended.

Classification: The Gartland System The classification is based on the degree of displacement of the distal fragment relative to the proximal fragment, as seen on a lateral radiograph.

Type I stable, nondisplaced fractures are managed non-operatively.

  • Treatment: Immobilization in a long-arm cast or splint for 3 to 4 weeks, typically in 90 degrees of flexion, followed by early mobilization .
  • Goal: Pain control and protection from further displacement. Type II FracturesThese fractures are unstable in extension but maintain some stability due to the intact posterior cortex. Management remains a point of controversy, with both conservative and surgical options being utilized.•Conservative Option: Closed reduction (CR) and casting, often reserved for less displaced or stable Type IIA fractures.•Surgical Option: Closed Reduction and Percutaneous Pinning (CRPP) is the preferred surgical method, especially for unstable Type IIB fractures (those with rotational instability).

Type III and IV are highly unstable fractures that require urgent intervention to achieve and maintain reduction .

Treatment: Closed Reduction and Percutaneous Pinning (CRPP) is the mainstay of treatment .Open reduction may be necessary if closed reduction fails or if there is a vascular compromise requiring exploration.

•Goal: Anatomical reduction and stable fixation to prevent malunion and neurovascular complications.

02

Conditions studied

  • Humeral Fractures

Browse trials for

03

In context

Humeral Fractures

106 studies on the registry are indexed under Humeral Fractures; 20 are open to participants now.

This study's planned enrollment of 50 is below the median of 56 across 64 interventional studies indexed under Humeral Fractures.

Browse Humeral Fractures studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Gartland type II supracondylar humerus fractures with age between 1-12 years old treated at the AUH

Exclusion criteria

Exclusion Criteria:

  • Gartland Type I, III, or IV fractures.
  • Open fractures.
  • Associated neurovascular injury (e.g., absent radial pulse, documented nerve palsy).
  • Patients with another injury in the same limb
  • Pathological fractures.
  • Pre-existing elbow pathology or congenital deformity.
  • Inability to comply with follow-up protocol.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Conservative treatment

    Children with Gartland type II supracondylar humeral fractures will be treated conservatively using closed reduction followed by immobilization in an above-elbow cast . Patients will be followed up clinically and radiologically at regular intervals to assess fracture alignment, healing, and functional outcomes.

    Other: Conservative treatment by casting

  • Experimental
    Surgical treatment group

    Children will undergo surgical treatment via Closed reduction and percutaneous pinning under general anesthesia. Postoperative follow-up will include clinical and radiological assessment of fracture healing, alignment, and complications.

    Procedure: surgical treatment via percutaneous pinning UGA

Interventions

  • OtherConservative treatment by casting

    Closed reduction of Gartland type II supracondylar humeral fracture under appropriate analgesia or anesthesia, followed by immobilization using an above-elbow cast. Patients will undergo regular clinical and radiographic follow-up to monitor fracture alignment, healing, and functional recovery.

  • Proceduresurgical treatment via percutaneous pinning UGA

    surgical treatment vis Closed reduction and percutaneous pinning under general anesthesia. Postoperative care includes clinical and radiographic follow-up to assess fracture healing, alignment, and potential complications.

06

What researchers measure

Primary outcomes

  1. Functional outcome assessed by Modified Disabilities of the Arm, Shoulder and Hand (QuickDASH) score

    Functional outcome will be evaluated using the Modified QuickDASH questionnaire. Scores range from 0 to 100, with higher scores indicating greater disability.

    Time frame: 1 year

Secondary outcomes

  1. Elbow flexion range of motion (degrees)

    Measured in degrees using a goniometer to assess maximum elbow flexion.

    Time frame: 1 month, 3 months, and 6 months post-intervention

  2. Elbow extension range of motion (degrees)

    Measured in degrees using a goniometer to assess maximum elbow extension.

    Time frame: 1 month, 3 months, and 6 months post-intervention

  3. Pain assessed using Visual Analog Scale (VAS)

    Pain is measured on a scale from 0 to 10, where 0 indicates no pain and 10 indicates worst possible pain.

    Time frame: 1 month, 3 months, and 6 months post-intervention

  4. Baumann angle (degrees)

    Measured on standard anteroposterior elbow radiographs to assess coronal alignment.

    Time frame: Immediately post-reduction and at 6 months

  5. Anterior humeral line alignment (normal/abnormal)

    Assessed on lateral elbow radiographs to evaluate sagittal alignment.

    Time frame: Immediately post-reduction and at 6 months

  6. Loss of reduction (yes/no)

    Defined as displacement of fracture fragments on follow-up radiographs.

    Time frame: Up to 6 months post-intervention

  7. Incidence of nerve injury (yes/no)

    Includes any documented motor or sensory nerve deficit following treatment.

    Time frame: Up to 6 months post-intervention

  8. Incidence of infection (yes/no)

    Includes superficial or deep infection related to treatment.

    Time frame: Up to 6 months post-intervention

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

Of 26 interventional studies with no phase under Humeral Fractures, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2026
First posted
Apr 30, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07558941
Lead sponsor
Assiut University
Responsible party
Ebraheem Ahmed Farouk Abdelraheem (Resident doctor at orthopedic department, Assiut University) — Principal investigator
First posted
Apr 30, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Apr 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion